Q3 2025 Cytosorbents Corp Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $0.6655 (+4.16%)

Transcript 8-K10-Q

Key Points

Positve

CytoSorbents Corp (CTSO) reported a 10% increase in revenue for Q3 2025, reaching $9.5 million, driven by record sales in distributor territories and strong results in direct markets.
The company's gross margin improved to approximately 70%, up from 61% in the same quarter of the previous year.
Core product sales reached a record $37 million over the trailing 12 months, supported by strong execution across the global network.
CytoSorbents Corp (CTSO) has a promising US regulatory path for its DrugSorb ATR, with plans to file a new de novo application in Q1 2026.
The company has implemented a strategic workforce and cost reduction program to achieve cash flow breakeven by Q1 2026, including a 10% workforce reduction and other cost-saving measures.

Negative

Direct sales in Germany declined by 3% to $12.6 million, highlighting challenges in the German market.
The FDA upheld the denial of the original de novo submission for DrugSorb ATR, requiring a new submission to address remaining open items.
Operating expenses for Q3 2025 were $9.5 million, with an increase in SG&A expenses due to regulatory spending and initial commercialization expenses.
The company's net loss for the quarter was $3.2 million, or $0.05 per share, compared to a net loss of $2.8 million in the prior year.
Cash equivalents and restricted cash decreased to $9.1 million as of September 30, 2025, reflecting a net operating cash burn of $2.6 million in the quarter.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTSO.OQ - Cytosorbents Corp
Q3 2025 Cytosorbents Corp Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen and welcome to the site of Soman Corp 3rd quarter 2025 earnings conference call. At this time online are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, November 13th of 2025.

I would now like to turn the conference over to Adana Alexander, investor relations consultant. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Chloe, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.